[
  {
    "ts": null,
    "headline": "AbbVie gains on Leerink Partners upgrade to Outperform",
    "summary": "AbbVie (ABBV) shares jump after Leerink Partners upgraded the stock to Outperform, saying the recent sell-off creates an opportunity for investors. The pharmaceutical stock tumbled earlier in the month after failing to meet the goals of its mid-stage trial for its schizophrenia drug, rivaling Bristol-Myers Squibb (BMY). Julie Hyman and Madison Mills break down what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=265a352e9dfbd5cf86a04643ed2a6842f7b9f54187ac3f65617f9e00435046dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732310615,
      "headline": "AbbVie gains on Leerink Partners upgrade to Outperform",
      "id": 131576248,
      "image": "https://s.yimg.com/ny/api/res/1.2/JtNtPHAQcHzoeVBEhDjT5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2024-11/13d828d0-a917-11ef-aff6-f17591824e69",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) shares jump after Leerink Partners upgraded the stock to Outperform, saying the recent sell-off creates an opportunity for investors. The pharmaceutical stock tumbled earlier in the month after failing to meet the goals of its mid-stage trial for its schizophrenia drug, rivaling Bristol-Myers Squibb (BMY). Julie Hyman and Madison Mills break down what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=265a352e9dfbd5cf86a04643ed2a6842f7b9f54187ac3f65617f9e00435046dd"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback",
    "summary": "AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.",
    "url": "https://finnhub.io/api/news?id=e219c247734270202cf219d281c4224563de7db9a4c37c63026cbe0709d4a14d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732309756,
      "headline": "AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback",
      "id": 131573730,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.",
      "url": "https://finnhub.io/api/news?id=e219c247734270202cf219d281c4224563de7db9a4c37c63026cbe0709d4a14d"
    }
  },
  {
    "ts": null,
    "headline": "J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis",
    "summary": "The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.",
    "url": "https://finnhub.io/api/news?id=275bb01c5c38b6266999a0af2d4c67cc3be614a8589f9d1864c2c64396f2d4fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732296351,
      "headline": "J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis",
      "id": 131567918,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/11/shutterstock_1828134221-e1732291233689.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at week 12.",
      "url": "https://finnhub.io/api/news?id=275bb01c5c38b6266999a0af2d4c67cc3be614a8589f9d1864c2c64396f2d4fa"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=2acc857155242f0e4b6c6d64cebcd77c8c3bee032a67153f1c9b2fbc40b66a58",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293300,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 131599135,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=2acc857155242f0e4b6c6d64cebcd77c8c3bee032a67153f1c9b2fbc40b66a58"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback",
    "summary": "AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.",
    "url": "https://finnhub.io/api/news?id=efd00853a4b81702e34a49a5f08254bc584c6e5bd1bb32f80cc4441a3d450730",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732293016,
      "headline": "AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback",
      "id": 131567920,
      "image": "",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.",
      "url": "https://finnhub.io/api/news?id=efd00853a4b81702e34a49a5f08254bc584c6e5bd1bb32f80cc4441a3d450730"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
    "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
    "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732288243,
      "headline": "AbbVie: Upgrading To 'Strong Buy' After Pullback",
      "id": 131571049,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153992734/image_2153992734.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVieâs high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy for long-term growth.",
      "url": "https://finnhub.io/api/news?id=0df10e1bcbeba0158dcbfaf1a9f8e50e0b4cf1c080a74bf9c7b958beb9447381"
    }
  }
]